Special Issue "Disease Progression in Multiple Sclerosis: Latest Therapeutic Developments and Future Directions"
Deadline for manuscript submissions: 14 February 2023 | Viewed by 802
Interests: multiple sclerosis; demyelinating disorders; neuroimmunology; neuroimaging; CSF biomarkers; real-world study; disease modifying treatment (DMT)
Multiple Sclerosis (MS) is the second leading cause of neurological disability in young adults after traumatic injuries. Clinically, MS can present as relapsing, remitting, or being characterized by a progressive disease course.
In the last 30 years, numerous therapies (disease-modifying therapies, DMTs) have been approved for MS treatment. These therapeutic approaches proved to be highly effective in reducing clinical relapses, as well as neuroradiological burden. However, DMTs have shown only partial efficacy in slowing the clinical deterioration in progressive forms of the disease. Indeed, in the MS research field, a major challenge is represented by the prediction of disease progression and accumulation. Disability accrual can occur as relapse-associated worsening (RAW) or steady progression independent of relapse activity (PIRA), with PIRA considered to be a feature of progressive MS.
This Special Issue aims to collect recent evidence (in form of original paper or as review) on the physiopathology of disease progression, treatment strategies for transitional and progressive forms of the disease, and biomarkers of progression in MS.
We are soliciting studies that explore potential pathological mechanisms of disease progression from in vivo approaches (such as studies on EAE model) to neurophysiological evaluations of patients. We also give priority to original papers evaluating potential markers of disease progression and disability accumulation, encompassing serum, cerebrospinal fluid, and neuroradiological biomarkers. We include a clinical study investigating potential predictors (both clinical and radiological ones) of long-term risk of disease progression. Finally, we intend to collect pharmacological studies, including both transitional (from relapsing-remitting to progressive) and progressive MS.
Dr. Matteo Lucchini
Dr. Serena Ruggieri
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- multiple sclerosis
- disease modifying treatment (DMT)
- magnetic resonance imaging
- progressive multipla sclerosis
- relapse-associated worsening (RAW)
- progression independent of relapse activity (PIRA)
- cerebrospinal fluid (CSF)